Sunitinib as an anti-endometriotic agent

Manal A. Abbas, Ahmad M. Disi, Disi AM, Mutasem O. Taha
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2013 · vol. 49(4) , pp. 732–736 · doi:10.1016/j.ejps.2013.05.021 · PMID:23747661 · W2021667437
article OA: closed CC0 ⤵ 15 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

Sunitinib, a receptor tyrosine kinase inhibitor, demonstrated anti-endometriotic effects by reducing lesion size and inhibiting angiogenesis in a preclinical model.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Endometriosis is one of the most frequent diseases in gynecology. Currently available medical therapies for this disease are unsatisfactory. Based on current understanding of the pathogenic mechanisms in endometriosis especially the similarity between this disease and cancer, this study was designed to investigate the efficacy of the anticancer drug sunitinib in treating endometriosis. The effect of sunitinib on regression of endometriotic implants was studied in a rat surgical model. Sunitinib reduced cyst cross sectional area by 78.8% and caused complete cyst disappearance in 50% of the animals. Histologically, extensive fibrosis was detected in sunitinib-treated group with positive reaction in TUNEL assay indicating that apoptosis is a mechanism of action.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Protein Kinase Inhibitors Animals Apoptosis Apoptosis Endometriosis Endometriosis Endometrium Endometrium Epithelial Cells Epithelial Cells Epithelial Cells Female Indoles Indoles In Situ Nick-End Labeling Protein Kinase Inhibitors Pyrroles Pyrroles Rats

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (28)

Cited by (15)

Source provenance

europepmc
last seen: 2026-08-14T06:11:53.302379+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:18:59.468224+00:00
unpaywall
last seen: 2026-08-14T06:25:32.811723+00:00
License: CC0 · commercial use OK